Who: Spark Therapeutics/NeuExcell Therapeutics
Roche Jumps Back Into Huntington’s With Spark/NeuExcell Partnership
Deal Snapshot: Roche gene therapy subsidiary Spark gets option and will partner with start-up NeuExcell on a Huntington’s gene therapy that researchers say may regenerate functional neurons.
More from Deals
• By
Several biotech execs said they don’t expect much impact from the Trump administration’s threatened tariffs but are reviewing business practices to prepare.
• By
The biopharma sector made acquisitions with total potential value of $33.6bn during Q1, up substantially from the $9.5bn of Q4 2024, according to data from Evaluate.
• By
Chinese biopharma companies’ alliance strategies are transitioning from immediate cash needs to more strategic management of portfolios, as MNCs continue to hunt for derisked assets.
• By
The biotech has rejected a takeover bid from Nordic Capital but a sale to private equity could be a solution to the public market's continued reluctance to adequately value PureTech’s hub-and-spoke business model.
More from Business
• By
A letter to US Senate HELP Committee Chair Bill Cassiday sounds an alarm about irreparable damage to the FDA, signed by more than 200 biotech executives and investors.
• By
Adstiladrin sales hit €70m in first full year on the market
• By
Evaluate data show that biopharma companies raising cash in the smallest and largest categories of venture capital financings struggled to meet bars set in prior quarters.